@htet33448: #fyp #foryoupage #ချစ်စရာလေး

H🍓🤍
H🍓🤍
Open In TikTok:
Region: MM
Saturday 31 October 2026 07:38:01 GMT
66233
11378
75
1849

Music

Download

Comments

xiaohu445
THET ZAW AUNG♊️🍀 :
ဟာ အားကျ
2026-10-31 10:47:31
5
naing.naing9011
💥𝙏𝙝𝙪𝙧𝙖 𝙉𝙖𝙞𝙣𝙜💥 :
ပျောက်လို့လိုက်ရှာနေတာကမ်းခြေရောက်နေတာကို😒
2026-10-31 16:52:04
0
swanhtetaung1530
swanhtetaung :
😁😁😁😁
2026-11-01 06:02:19
0
y8834z
Y🍀 :
2026-10-31 09:41:56
1
khaing.zarni.aung2
Khaing Zarni Aung :
မိုက်လိုက်တာ မမရယ် တော်တော်လေးလှတယ် 🥰🥰🥰🥰
2026-10-31 16:52:47
0
nyaeinchamthu4
𝕟𝕪𝕖𝕚𝕟 𝕔𝕙𝕒𝕟 𝕥𝕙𝕦🇲🇲 :
ဒါမျိုးတစ်ခါမှ မစားဘူးဘူး🥺🥺နည်းနည်းလောက်🤣🤣
2026-10-31 14:43:42
0
nofficial11
N & Official & :
ဘာတွေရောင်းတာလဲဗျ
2026-10-31 14:42:22
0
kumheaei
H A S Xein :
တကရ်ပ့...မမရာ.. သိပ်လှတဲ့သက်တန့်ရီးတောင် ကွေ့လောက်ပ့တရ်🤭🤭🤭🤭🤟🤟💙🩵🩵🫶
2026-10-31 13:24:36
0
phase.sone7
phase sone :
လှတယ်သဘောကျတယ်
2026-10-31 11:12:20
1
si.thu39871
si thu ဧရာဝတီသားလေး :
မိုက်တာချစ်စရာချင်းစရာယေး❤️❤️
2026-10-31 19:17:46
0
cho.yi.mon.zaw
🌸Cxo🌸 :
အရမ်းမိုက်တယ် မမယေ🥰❤️❤️🫶
2026-10-31 13:12:18
0
feel4403
ကျေးလက် အညာသားလေးပါဗျာ :
ချစ်စယာလေးကွာ😉🥰🥰
2026-10-31 17:58:05
0
minhlaing96
Min Hlaing :
လှလား
2026-10-31 12:56:34
0
kowin0138
🥰🤫mix🤟🥰 :
ပန်းယေးလှလိုက်တာ😍ဥယာဥ်မှုးယေးရှိမှာပေါ့😔
2026-10-31 12:57:11
0
htutoonaung3
Htut Naung :
မမရေလို
2026-10-31 16:05:34
0
thaunglwinphyo0
𝚃ʰᵃᵘⁿᵍ𝙻ʷⁱⁿ𝙿ʰʸᵒ♉ :
2026-10-31 09:12:20
0
indubai14
Taub ullah. :
🤎🤎🤎🤎🤎🤎🤎🤎🤎🤎🤎🤎🤎
2026-10-31 15:56:14
0
thar.thar069
Thar Thar :
😳😳😳❤️❤️❤️❤️❤️
2026-10-31 09:10:50
1
zayar4620
Zayar :
🥰🥰🥰🥰🥰🥰🥰
2026-10-31 12:03:20
0
heinmgmg357
ĥêîñ mĝ🇲🇲🇲🇾 :
မောင်လေးရဲ့အချစ်တေအကုန်ပုံပေးလိုက်ချင်တယ်ဗျာမမရယ်
2026-10-31 12:28:55
0
crazy1102007
Toxic💐 :
အဲ့အကျီလေးဘယ်က၀ယ်တာလဲ
2026-11-01 08:09:02
0
my.future667
myo gyi :
မိုက်တယ်🥰🥰😁😁
2026-10-31 12:09:56
0
kaung.myat1383
K :
2026-10-31 12:38:10
0
phyophyothet8
第二人称 :
2026-10-31 12:35:12
0
john.official.19
JOHN^ဂျွန်^ :
2026-10-31 09:18:23
0
To see more videos from user @htet33448, please go to the Tikwm homepage.

Other Videos

GLP-1 receptor agonists are known for diabetes and weight, but a fast-growing body of research suggests they’re also broadly anti-inflammatory and immune-modulating. A 2025 systematic review described effects well beyond metabolism, including emerging interest in autoimmune and neurological conditions. The most direct evidence for MCAS so far is a single 2025 retrospective case series: 47 patients with treatment-resistant MCAS, 89% of whom showed clinical benefit, often within hours to days, across inflammatory, gastrointestinal, neurologic, and autonomic symptoms. Mechanistically, mast cells carry GLP-1 receptors, and these drugs dampen inflammatory pathways like TNF-alpha and NF-kB, which may explain it. The limitations matter and the hype skips them: this was retrospective, single-group, with NO control or placebo, and the authors themselves state that randomized controlled trials are needed before any of this is established. GLP-1 medications are serious prescription drugs with real side effects, real costs, and access issues, and they are NOT a proven or standard MCAS treatment. This is a promising research lead, not a recommendation. I’m not a doctor or scientist. Talk to a clinician who knows your history. Has anyone here been on a GLP-1 and noticed other symptoms change? Curious what you actually experienced. Sources: Afrin LB, Weinstock LB, Dempsey TT, Aschenbrenner K, Blitshteyn S, Schofield JR. Utility of GLP-1 receptor agonists in mast cell activation syndrome. Am J Med Sci. 2025;370(4):377-382. DOI: 10.1016/j.amjms.2025.07.006. Patel S, Niazi SK. Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base. Pharmaceutics. 2025. DOI: 10.3390/pharmaceutics17081036. Alharbi SH. Anti-inflammatory role of GLP-1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024. DOI: 10.1177/20420188231222367. #mcas #mastcellactivationsyndrome #glp1 #semiglutide #autoimmune
GLP-1 receptor agonists are known for diabetes and weight, but a fast-growing body of research suggests they’re also broadly anti-inflammatory and immune-modulating. A 2025 systematic review described effects well beyond metabolism, including emerging interest in autoimmune and neurological conditions. The most direct evidence for MCAS so far is a single 2025 retrospective case series: 47 patients with treatment-resistant MCAS, 89% of whom showed clinical benefit, often within hours to days, across inflammatory, gastrointestinal, neurologic, and autonomic symptoms. Mechanistically, mast cells carry GLP-1 receptors, and these drugs dampen inflammatory pathways like TNF-alpha and NF-kB, which may explain it. The limitations matter and the hype skips them: this was retrospective, single-group, with NO control or placebo, and the authors themselves state that randomized controlled trials are needed before any of this is established. GLP-1 medications are serious prescription drugs with real side effects, real costs, and access issues, and they are NOT a proven or standard MCAS treatment. This is a promising research lead, not a recommendation. I’m not a doctor or scientist. Talk to a clinician who knows your history. Has anyone here been on a GLP-1 and noticed other symptoms change? Curious what you actually experienced. Sources: Afrin LB, Weinstock LB, Dempsey TT, Aschenbrenner K, Blitshteyn S, Schofield JR. Utility of GLP-1 receptor agonists in mast cell activation syndrome. Am J Med Sci. 2025;370(4):377-382. DOI: 10.1016/j.amjms.2025.07.006. Patel S, Niazi SK. Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base. Pharmaceutics. 2025. DOI: 10.3390/pharmaceutics17081036. Alharbi SH. Anti-inflammatory role of GLP-1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024. DOI: 10.1177/20420188231222367. #mcas #mastcellactivationsyndrome #glp1 #semiglutide #autoimmune

About